Invokana (canagliflozin) for the Treatment of Type 2 Diabetes

Invokana (canagliflozin) is indicated to improve glycemic control in adults with type 2 diabetes, along with diet and exercise. It was first developed by Mitsubishi Tanabe Pharma Corporation in Japan and later licensed to Janssen Pharmaceuticals.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news